Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation

Chin Med J (Engl). 2023 Apr 5;136(7):848-850. doi: 10.1097/CM9.0000000000002453.

Authors

Shiqi Mao¹, Libo Luo¹, Shuo Yang¹, Yan Wang¹, Fei Zhou¹, Jia Yu¹, Bin Chen¹, Guanghui Gao¹, Xuefei Li², Chao Zhao², Lei Cheng², Yiwei Liu¹, Wanying Wang¹, Keyi Jia¹, Chuchu Shao¹, Xinyu Liu¹, Xiaoxia Chen¹, Chunxia Su¹, Caicun Zhou¹, Fengying Wu¹, Shengxiang Ren¹

Affiliations

¹ Department of Medical Oncology, Shanghai Pulmonary Hospital, Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.
² Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.

No abstract available

MeSH terms

Aminoquinolines / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation / genetics
Standard of Care

Substances

Aminoquinolines
pyrotinib
ERBB2 protein, human